Related references
Note: Only part of the references are listed.Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models
Takahito Nakahara et al.
CANCER SCIENCE (2011)
Organic Cation Transporter-Mediated Renal Secretion of Ipratropium and Tiotropium in Rats and Humans
Takeo Nakanishi et al.
DRUG METABOLISM AND DISPOSITION (2011)
Utility of P-Glycoprotein and Organic Cation Transporter 1 Double-Transfected LLC-PK1 Cells for Studying the Interaction of YM155 Monobromide, Novel Small-Molecule Survivin Suppressant, with P-Glycoprotein
Megumi Iwai et al.
DRUG METABOLISM AND DISPOSITION (2011)
Characterization of Human Organic Cation Transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-Mediated Transport of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small Molecule Survivin Suppressant
Tsuyoshi Minematsu et al.
DRUG METABOLISM AND DISPOSITION (2010)
Carrier-Mediated Uptake of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small-Molecule Survivin Suppressant, into Human Solid Tumor and Lymphoma Cells
Tsuyoshi Minematsu et al.
DRUG METABOLISM AND DISPOSITION (2009)
Involvement of Human Organic Cation Transporter 1 in the Hepatic Uptake of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel, Small Molecule Survivin Suppressant
Megumi Iwai et al.
DRUG METABOLISM AND DISPOSITION (2009)
Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non-Small-Cell Lung Cancer
Giuseppe Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma
Tsuyoshi Minematsu et al.
BIOMEDICAL CHROMATOGRAPHY (2008)
Role of organic anion transporters in the pharmacokinetics of zonampanel, an α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats
Tsuyoshi Minematsu et al.
DRUG METABOLISM AND DISPOSITION (2008)
Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts
Takahito Nakahara et al.
CANCER RESEARCH (2007)
Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications
Hermann Koepsell et al.
PHARMACEUTICAL RESEARCH (2007)
A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters
H Tahara et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk
JW Jonker et al.
NATURE MEDICINE (2005)
Xenobiotic transporter expression and function in the human mammary gland
S Ito et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
The presence of xenobiotic transporters in rat placenta
TM Leazer et al.
DRUG METABOLISM AND DISPOSITION (2003)
Kinetic analysis of P-glycoprotein-mediated transport by using normal human placental brush-border membrane vesicles
F Ushigome et al.
PHARMACEUTICAL RESEARCH (2003)
Tissue distribution and renal developmental changes in rat organic cation transporter mRNA levels
AL Slitt et al.
DRUG METABOLISM AND DISPOSITION (2002)
Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin
DS O'Connor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
